Southlake, TX – According to filings with the U.S. Securities and Exchange Commission, Renibus Therapeutics is raising $33,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Frank Stonebanks played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Renibus Therapeutics
Renibus Therapeutics is a clinical-stage biotech company dedicated to transforming the cardiorenal disease treatment paradigm by focusing on the prevention and treatment of kidney disease. The company’s portfolio includes RBT-1 for prevention of acute kidney injury, RBT-2 for treatment of chronic kidney disease, and RBT-3 for treatment of iron deficiency anemia and platinum-based kidney toxicity.

To learn more about Renibus Therapeutics, visit http://www.renibus.com/

Contact:
Frank Stonebanks, Chief Executive Officer
682-285-1711
https://www.linkedin.com/in/sokoboy/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved